Cardiovascular Disease in Cullman, AL
3 verified cardiovascular disease doctors in Cullman.
Cardiologists diagnose and treat conditions of the heart and blood vessels, including heart disease, arrhythmias, and heart failure.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Edward Mahan, MD
Cardiovascular Disease
CMS Open Payments· $414.28 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$414.28
Total received
24
Transactions
13
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total ranks around the 61th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to Edward Mahan do not imply any wrongdoing. Many are meals, education, or research support.
Dr. James Lee, MD
Cardiovascular Disease
CMS Open Payments· $434.57 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$434.57
Total received
25
Transactions
10
Paying companies
Top paying companies
Among the 26,323 cardiovascular disease doctors we've analyzed, about 66% received any industry payment (median $653 among those who did). This doctor's total ranks around the 62th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US cardiovascular disease doctors.
Payments to James Lee do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Daniel Gonzalez Abascal, MD
Cardiovascular Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.